Opening Comments at the American Association for the Advancement of Science (AAAS) consultation on Human Enhancement
By Richard Hayes
| 06. 01. 2006
Mark Frankel asked if we’d share some general perspectives on what we believe to be the major challenges posed as we consider technologies of “enhancement.” I’d like to share the perspective of the Center for Genetics and Society, as well as what we’ve learned about the perspectives of a wide range of Americans and others.
CGS got started following a series of meetings held in 2000 on the social and political implications of the new human genetic technologies. The meetings brought together people concerned about social and economic justice, women’s health and reproductive rights, science and society, environmental protection, and the rights of the disabled.
Those participating became concerned when they learned how rapidly these new technologies were being developed, how profoundly consequential these could be, how thin were the few rules and regulations in place, and how well below the radar screens of both the general public and policy makers all this was.
A major concern was that use of these technologies could greatly exacerbate human inequality, in particular through a revival of eugenic technologies and ideologies, this time...
Related Articles
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...